Sign in

    Joseph on for Mike Matson

    Senior Analyst at Needham

    Mike Matson is a Senior Analyst at Needham & Company specializing in Medical Technologies and Diagnostics, providing equity research on leading firms such as Johnson & Johnson, Boston Scientific, Medtronic, Abiomed, and Shockwave Medical. Renowned for his rigorous analysis, Matson ranks among the industry’s top performers, including first place for stock picking in the Health Care Equipment & Supplies sector in the Thomson Reuters Analyst Awards and a Top Ten ranking by TipRanks, with notable accuracy in earnings estimates. He began his analyst career after working at Stryker and advanced through roles at Wells Fargo Securities and Mizuho Securities before joining Needham in 2013. Matson holds a BS in Mechanical Engineering, an MBA with Health Sector Management specialization, CFA certification, and a U.S. medical device patent.

    Joseph on for Mike Matson's questions to NARI leadership

    Joseph on for Mike Matson's questions to NARI leadership • Q1 2024

    Question

    Asked about the reason for the Q1 gross margin decline, whether pricing was a factor, and for clarification on the use of bundled pricing for complex cases.

    Answer

    The gross margin decline was attributed to product mix, new product ramp-up costs, and internationalization, not pricing pressure. Pricing has been stable to up. The company clarified that 15-20% of VTE procedures are complex cases where physicians benefit from using a bundled toolkit of both ClotTriever and FlowTriever products.

    Ask Fintool Equity Research AI